Ivacaftor (VX-770, trade name Kalydeco, Vertex Pharmaceuticals) is the first CFTR modulator approved for clinical use in CF patients aged 6 and above by the Food and Drug Administration (FDA). This evidence concerns the gene CFTR and cystic fibrosis.